Literature DB >> 15937356

Use of interferon-gamma ELISPOT in monitoring immune responses in humans.

Mark Matijevic1, Robert G Urban.   

Abstract

The interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay has become a useful tool for immunologists seeking to quantify immune responses on a per-cell basis. The assay is sensitive and allows for the enumeration of low-frequency T-cells. Many have applied this assay to clinical trials as a way to measure biological activity in a patient cohort. It is critical that each laboratory attempting to use the assay in their facility perform rigorous development and qualification work to establish an assay that suits their particular needs. This chapter serves as a demonstration of two practical and slightly different approaches to using the ELISPOT assay to monitor immune activity in the human periphery: (1) assays using whole samples of peripheral blood mononuclear cells with and without the use of additional antigen presenting cells and (2) assays using enriched T-cell populations. Detailed protocols and procedures will be covered, as well as a demonstration of results obtained from three separate applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937356     DOI: 10.1385/1-59259-903-6:237

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Authors:  Joseph I Clark; James Moon; Laura F Hutchins; Jeffrey A Sosman; W Martin Kast; Diane M Da Silva; P Y Liu; John A Thompson; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

2.  Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.

Authors:  Mark Matijevic; Mary Lynne Hedley; Robert G Urban; Roman M Chicz; Christa Lajoie; Thomas M Luby
Journal:  Cell Immunol       Date:  2011-04-23       Impact factor: 4.868

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.